Iodide in Goitre due to P.A.S

Macgregor, Alastair G.; Somner, A. R.

doi:10.1136/bmj.1.4877.1494-a

BMJ

1954

DOI: 10.1136/bmj.1.4877.1494-a

|View full text |Cite

Iodide in Goitre due to P.A.S

Alastair G. Macgregor¹,

A. R. Somner²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1954

2015

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…inhibits the formation of di-iodotyrosine and thyroid hormone, and the action is a direct one, although the possibility of an additional indirect action cannot be entirely excluded. Macgregor and Somner (1954) and Brinkman and Coates (1954) found iodine ineffective in the relief of goitre due to P.A.S., but remissions of the symptoms and goitre were seen following the use of thyroid. Balint et al (1954) reported some benefit from iodine.…”

mentioning

confidence: 97%

Hyperthyroidism Developing During P.A.S. Therapy

Tandhanand¹,

Buri²

1956

BMJ

View full text Add to dashboard Cite

mentioning

confidence: 97%

Hyperthyroidism Developing During P.A.S. Therapy

Tandhanand¹,

Buri²

1956

BMJ

View full text Add to dashboard Cite

Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications

Ramachandran

Swaminathan

2015

Drug Saf

View full text Add to dashboard Cite

Tuberculosis (TB) remains a major public health problem, representing the second leading cause of death from infectious diseases globally, despite being nearly 100 % curable. Multidrug-resistant (MDR)-TB, a form of TB resistant to isoniazid and rifampicin (rifampin), two of the key first-line TB drugs, is becoming increasingly common. MDR-TB is treated with a combination of drugs that are less effective but more toxic than isoniazid and rifampicin. These drugs include fluoroquinolones, aminoglycosides, ethionamide, cycloserine, aminosalicyclic acid, linezolid and clofazimine among others. Minor adverse effects are quite common and they can be easily managed with symptomatic treatment. However, some adverse effects can be life-threatening, e.g. nephrotoxicity due to aminoglycosides, cardiotoxicity due to fluoroquinolones, gastrointestinal toxicity due to ethionamide or para-aminosalicylic acid, central nervous system toxicity due to cycloserine, etc. Baseline evaluation may help to identify patients who are at increased risk for adverse effects. Regular clinical and laboratory evaluation during treatment is very important to prevent adverse effects from becoming serious. Timely and intensive monitoring for, and management of adverse effects caused by, second-line drugs are essential components of drug-resistant TB control programmes; poor management of adverse effects increases the risk of non-adherence or irregular adherence to treatment, and may result in death or permanent morbidity. Treating physicians should have a thorough knowledge of the adverse effects associated with the use of second-line anti-TB drugs, and routinely monitor the occurrence of adverse drug reactions. In this review, we have compiled safety and tolerability information regarding second-line anti-TB drugs in both adults and children.

show abstract

The antibacterial therapy of tuberculosis

Ross

1958

Tubercle

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Iodide in Goitre due to P.A.S

Cited by 5 publications

References 1 publication

Hyperthyroidism Developing During P.A.S. Therapy

Hyperthyroidism Developing During P.A.S. Therapy

Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications

The antibacterial therapy of tuberculosis

Contact Info

Product

Resources

About